Skip To Main Content
Cheng-Hao Tseng on Muck Rack

Cheng-Hao Tseng

As seen in: Wiley Online Library, Gut Journal, MDPI, The Lancet, Gastrointestinal Endoscopy, JHEP Reports
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cheng-Hao

Contact Cheng-Hao, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis B

|
By Edward J Gane, Chi-Yi Chen, Cheng-Hao Tseng
| Wiley Online Library Verified
Conflicts of Interest E.J.G. served as an advisor for AbbVie; Aligos Therapeutics; Arbutus Biopharma; Gilead Sciences Inc.; Janssen; Roche; Vir Biotechnology; and Virion Therapeutics. C.-Y.C., C.-Y.L., and S.K.R. report no conflicts of interest. C.-H.T. reports payments for lectures from Roche, Eisai, and Merck Sharp & Dohme.
Open in Who Shared Issue with article?

Su2167 GLOBAL ANTIVIRAL TREATMENT RATES AND SURVIVAL OUTCOMES IN HEPATITIS B VIRUS-RELATED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 82 STUDIES AND 71,419 PATIENTS

|
By Sahith Kudaravalli, Taotao Yan, Cheng-Hao Tseng, Yao-Chun Hsu, Xiaohe Li, Yuankai Wu, Bowu Chen, Warren Sands, Ramsey Cheung, Mindie Nguyen
| Gastrointestinal Endoscopy Verified
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Open in Who Shared View Duplicates (465) Issue with article?

Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss

|
By Ying-Nan Tsai, Jia-Ling Wu, Cheng-Hao Tseng
| Wiley Online Library Verified
ALT alanine transaminase ant-HBc antibody against hepatitis B core antigen anti-HBe antibody to hepatitis B e antigen AST aspartate aminotransferase AUC area under the curve CF clinical flare CHB chronic hepatitis B CI confidence interval CR clinical relapse EOT end of treatment HBcrAg hepatitis B core-related antigen HBeAg hepatitis B e antigen HBsAg hepatitis B surface antigen HBV hepatitis B virus HCC hepatocellular carcinoma HCV hepatitis C virus HDV hepatitis D virus HIV human...
Open in Who Shared Issue with article?
See all 13 articles